1

Abstract Implosionism, Cerealism photos at Davis Orton Gallery, in Hudson, NY

Enjoyed last night’s opening at the Davis-Orton Gallery  114 Warren St. in  Hudson, NY  (legit for this blog: Karen Davis and Mark Orton recently moved from Cambridge, MA and Karen is still teaching a photography workshop at Lesley College). The show features the work of John Chervinsky of Somerville, MA and Ernie Button, of Phoenix, AZ.

  

Chervinsky uses a complex process to come up with photos combining  still life, landscape, abstraction, hyperrealism, outer space and laboratory chalkboard diagrams –showing objects in spatial perspectives  that simultaneously intrigue and perplex  the viewer, as in  “Abstract Implosionism, ” above, left).

 “I see these photographs as posing questions without easy answers. My intent is not to express a single, narrow perspective, but to, among other things, expose the fallacy of doing so,” Chervinsky writes. 

While looking at one photograph, curator Karen Davis remarked, “I really like this pitcher.” It was a picture of a pitcher…somehow suspended in space with string that appeared to come from nowhere.

Ernie Button’s “Cerealism” is a set of landscapes composed of breakfast cereal arrangements (tho there is one of French toast). On first (and second) viewing, they appear to be abstracts of fields, deserts, the pyramids…but on closer look (at the titles, especially) you see that they are bits of Cap’n Crunch, Cheerios, and other breakfast edibles, sometimes color treated to create what the gallery writeup calls ” a magical quality and an odd sense of ‘reality’”. 

Much of Ernie Button’s imagery focus on the individual nature of objects and the unique qualities that each possesses.  “My images often provide a voice to objects that are ignored and are frequently overlooked or taken for granted,” Button writes.

It’s an  unusual and fun show, great in combination, not to be missed if you’re in the area.

Through September 19, 2010,

–Anita M. Harris

New Cambridge Observer is a publication of the Harris Communications Group of Cambridge, MA.




Non-invasive test predicts risk of sudden cardiac arrest

I’m  helping Cambridge Heart and Kogs Communications get out the good news that the company’s non-invasive test, which is administered much like a stress test, on a treadmill, accurately predicts the risk of sudden cardiac arrest–the leading killer in the US.

Here’s today’s release:

Tewksbury, Mass., March 3, 2009 – Cambridge Heart, Inc. (OTCBB-CAMH), today announced the publication of five articles supporting the use of Microvolt T Wave Alternans™ (MTWA) testing in a supplement to the March issue of the Heart Rhythm journal. Featured in the supplement is a comprehensive meta-analysis of 6,000 patients confirming the value of MTWA as a non-invasive marker of risk for sudden cardiac arrest (SCA).

The MTWA test, administered much like a stress test on a treadmill, was developed by Cambridge Heart as a diagnostic tool to help physicians determine a patient’s risk of sudden cardiac arrest — the leading cause of death in the United States.

The meta-analysis, conducted by a group led by Stefan Hohnloser, MD, FHRS, of the JW Goethe University Division of Cardiology in Frankfurt, Germany, assessed 13 MTWA clinical studies involving approximately 6,000 cardiac patients.

“The results demonstrate that MTWA testing is a consistently accurate predictor of sudden cardiac death and cardiac arrest in patients who do not already have implantable cardiac defibrillators (ICDs),” said Dr. Stefan Hohnloser. “These are the patients for whom MTWA testing is intended.”

The meta-analysis authors also conclude that:

· Patients who test negative for MTWA abnormalities are at extremely low risk (0.3%) for SCA in the next 12 months.

· MTWA testing can help doctors guide ICD therapy to appropriate patients and overcome the widespread reluctance of patients and referring physicians to accept ICD therapy.

· In clinical trials, appropriate ICD shocks are an unreliable surrogate endpoint for SCA and can skew results of risk stratification studies.

“This comprehensive analysis confirms the findings of numerous peer-reviewed studies which underscore the important role of MTWA in assessing a patient’s risk of sudden cardiac arrest,” said Ali Haghighi-Mood, PhD, Chief Executive Officer of Cambridge Heart.

The Heart Rhythm supplement also includes:

· A second meta-analysis of MTWA testing in patients with non-ischemic heart disease, authored by Gaetano De Ferrari, MD and Antonio Sanzo, MD of the Department of Cardiology at Fondazione IRCCS Policlinico San Matteo, Pavia Italy. Analyzing eight available trials involving 1,450 patients, the paper indicates that in this population negative MTWA results can help patients and their physicians decide whether ICD therapy may safely be avoided.

· An article by Michael J. Mirro, MD, Medical Director of the Parkview Health System Clinical Research Center in Fort Wayne Indiana, who describes how his center has incorporated MTWA testing into clinical practice to complement other methods for identifying and educating patients about the risk of SCA.

· A review of numerous studies concerning the underlying cellular mechanisms of T-wave alternans. The authors conclude that microvolt T-wave alternans is a marker of cellular changes that make the heart susceptible to sudden cardiac arrest. The review was carried out by Michael Cutler, DO, PhD, and David S. Rosenbaum, MD, of the Heart and Vascular Research Center at the Department of Biomedical Engineering at Case Western Reserve University in Cleveland.

· A review by Navinder Sawhney, MD and Sanjiv Narayan, MD of the University of California at San Diego that underscores the value of MTWA testing in patients who have had heart attacks but do not fall within current guidelines for ICD implantation.

The articles in the supplement can be found on the Heart Rhythm journal website at:

http://www.heartrhythmjournal.com/issues/contents?issue_key=S1547-5271(09)X0006-8

About Cambridge Heart, Inc.

Cambridge Heart develops and commercializes non-invasive diagnostic tests for cardiac disease, with a focus on identifying those at risk for sudden cardiac arrest (SCA). The Company’s products incorporate proprietary Microvolt T-Wave Alternans measurement technologies including the patented Analytic Spectral Method® and ultrasensitive disposable electrode sensors. Medicare reimburses the Analytic Spectral Method® under its National Coverage Policy. Cambridge Heart, founded in 1990, is based in Tewksbury, MA. The company’s Microvolt T-Wave Alternans™ (MTWA) test, developed by Cambridge Heart (OTCBB: CAMH), is based on research originally conducted at the Massachusetts Institute of Technology. http://www.cambridgeheart.com.

Statements contained in this press release are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In some cases, we use words such as “believes”, “expects”, “anticipates”, “plans”, “estimates”, “could”, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements. Factors that may cause or contribute to such differences include failure to achieve broad market acceptance of the Company’s MTWA technology, failure of our sales and marketing organization to market our products effectively, inability to hire and retain qualified clinical applications specialists in the Company’s target markets, failure to obtain or maintain adequate levels of third-party reimbursement for use of the Company’s MTWA test, customer delays in making final buying decisions, decreased demand for the Company’s products, failure to obtain funding necessary to develop or enhance our technology, adverse results in future clinical studies of our technology, failure to obtain or maintain patent protection for our technology and other factors identified in our most recent Annual Report on Form 10‑K/A under “Risk Factors”, which is on file with the SEC and available at www.EDGAR.com. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so except as may be legally necessary, even if our estimates should change.

The New Cambridge Observer is a publication of the Harris Communications Group of Cambridge, MA.




Scientia Advisors Presents Webinars on Medical Industries

Thought you might like to know that my client, Scientia Advisors, is offering five free Webinars aimed at helping major corporations, emerging companies and innovative startups choose strategic directions.

The Webinars, in February, 2009, will present Scientia’s latest industry reviews. The reviews are based on interviews with scientists, clinicians, manufacturers, and product developers as well as on traditional market research.

The Webinars will initially be presented live, with opportunities for interactive participation.  Less-detailed Webcasts will subsequently be available for download from the Scientia Advisors Web site.

Here’s the schedule; click on any of the titles for more information or to register.
Anita


· Riding the High Value In Vitro Diagnostics Wave: Translating Promise Into Clinical Reality With Managing Partner Harry Glorikian, 11 AM Tuesday, February 10

· Back to the Future: Cell Market Entrance Strategies, Post-Stem Cell Deregulation

With Partner Arshad Ahmed, 11 AM Wednesday, February 11

· Drivers of Success in Functional Foods
With Principal Bob Jones 2 PM Wednesday, February 11

· Molecular Diagnostics: Identifying Candidates for Success in an Innovation-Driven Market

With Harry Glorikian, 11 AM Thursday, February 12

· Point of Care: Enabling Broad Product Adoption Through Maximized Access to Health Care Sites
With Harry Glorikian, 11 AM Thursday, February 19

Scientia Advisors, based in Cambridge, MA and Palo Alto, CA, is an international management consulting firm specializing in growth and operational strategies for major and emerging companies in health care, life science and biotechnology.

New Cambridge Observer is a publication of the Harris Communications Group, of Cambridge, MA.




For a free press–please pay!

With the ever increasing fall of bookstores and impending newspaper layoffs, I’d like to echo Alex Beam’s call for readers to reach for their wallets.

In case you missed his January 9 column, “Closing Costs,” in the Boston Globe, it opens: “Here is a dispatch from the Land of No Suprises: Bookstores–buffed by the recession, by Amazon, by electronic reading devices–are closing their doors”. He points out that, easy as it is to go to Amazon for books and read newspapers online for free, by behaving normally, “you kill the things you love.”

In Boston, after several waves of reporter buyouts, people keep telling me that they’ve dropped their subscriptions to the Globe because it’s gone downhill, and, anyway, they can get it on line, for free. Duh.

My apologies for stating the obvious, but many of my friends don’t seem to get that, in  a vicious financial cycle,  with fewer paying customers,   the paper can get fewer advertisers, revenues go down, and, as a result, the Globe and many other papers have had to  “encourage”  their most senior,  talented reporters to leave.  The Globe announced  a new round of editorial layoffs just last week.

I’ll be writing more about this–but for the time being, please support the  free press–by paying for it.

The New Cambridge Observer is a publication of the Harris Communications Group, of Cambridge, MA.